Acorda Therapeutics Inc (ACOR) Receives $29.45 Average PT from Analysts

Acorda Therapeutics Inc (NASDAQ:ACOR) has been assigned a consensus rating of “Buy” from the twelve analysts that are presently covering the stock. Six research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $29.45.

A number of research analysts have recently commented on ACOR shares. Cowen and Company set a $60.00 target price on Acorda Therapeutics and gave the company a “buy” rating in a research note on Tuesday, January 3rd. Stifel Nicolaus reaffirmed a “buy” rating and set a $30.00 target price on shares of Acorda Therapeutics in a research note on Thursday, March 30th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $21.00 target price on shares of Acorda Therapeutics in a research note on Monday, January 9th. Zacks Investment Research cut Acorda Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 23rd. Finally, Goldman Sachs Group Inc raised Acorda Therapeutics from a “sell” rating to a “neutral” rating in a research note on Wednesday, February 15th.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://sportsperspectives.com/2017/04/21/acorda-therapeutics-inc-acor-receives-29-45-average-pt-from-analysts.html.

A number of institutional investors have recently modified their holdings of ACOR. State of Alaska Department of Revenue raised its position in shares of Acorda Therapeutics by 2.6% in the first quarter. State of Alaska Department of Revenue now owns 5,120 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 130 shares during the period. Municipal Employees Retirement System of Michigan raised its position in shares of Acorda Therapeutics by 1.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 10,220 shares of the biopharmaceutical company’s stock worth $213,000 after buying an additional 160 shares during the period. Louisiana State Employees Retirement System raised its position in shares of Acorda Therapeutics by 2.2% in the first quarter. Louisiana State Employees Retirement System now owns 18,900 shares of the biopharmaceutical company’s stock worth $397,000 after buying an additional 400 shares during the period. Capstone Asset Management Co. raised its position in shares of Acorda Therapeutics by 6.4% in the first quarter. Capstone Asset Management Co. now owns 12,940 shares of the biopharmaceutical company’s stock worth $272,000 after buying an additional 781 shares during the period. Finally, Rhumbline Advisers raised its position in shares of Acorda Therapeutics by 1.7% in the third quarter. Rhumbline Advisers now owns 67,055 shares of the biopharmaceutical company’s stock worth $1,400,000 after buying an additional 1,125 shares during the period.

Shares of Acorda Therapeutics (NASDAQ:ACOR) traded down 0.63% during trading on Tuesday, hitting $15.85. The stock had a trading volume of 782,788 shares. Acorda Therapeutics has a 12 month low of $15.60 and a 12 month high of $33.00. The stock has a 50 day moving average of $23.13 and a 200 day moving average of $21.41. The company’s market cap is $723.82 million.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Tuesday, February 14th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.23. Acorda Therapeutics had a negative return on equity of 1.66% and a negative net margin of 4.38%. The business had revenue of $140.63 million for the quarter, compared to the consensus estimate of $137.90 million. During the same period in the prior year, the business posted $0.28 earnings per share. The company’s quarterly revenue was up 2.4% compared to the same quarter last year. Equities analysts forecast that Acorda Therapeutics will post $1.47 EPS for the current fiscal year.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS).

5 Day Chart for NASDAQ:ACOR

Receive News & Ratings for Acorda Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply